STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.

Autosomal dominant polycystic kidney disease (ADPKD) leads to renal failure. The hallmark of ADPKD is increased epithelial proliferation, which has been proposed to be due to atypical signaling including abnormal JAK-STAT activity. However, the relative contribution of JAK-STAT family members in promoting proliferation in ADPKD is unknown. Here, we present siRNA JAK-STAT-focused screens discovering a previously unknown proliferative role for multiple JAK-STAT components (including STAT1, STAT2, STAT4, STAT5a, and STAT5b). Amongst these, we selected to study the growth hormone/growth hormone receptor/STAT5-axis because of its known role as a regulator of growth in nonrenal tissues. Loss of STAT5 function, facilitated by pharmacological inhibition or siRNAs, significantly reduced proliferation with an associated reduction in cyst growth in vitro. To study whether STAT5 is abnormally activated in vivo, we analyzed its expression using two independent mouse models of ADPKD. STAT5 was nuclear, thus activated, in renal epithelial cyst lining cells in both models. To test whether forced activation of STAT5 can modulate proliferation of renal cells in vivo, irrespective of the Pkd1 status, we overexpressed growth hormone. These mice showed increased STAT5 activity in renal epithelial cells, which correlated with de novo expression of cyclin D1, a STAT5 target gene. Chromatin immunoprecipitation experiments revealed that STAT5 transcriptionally activated cyclin D1 in a growth hormone-dependent fashion, thus providing a mechanism into how STAT5 enhances proliferation. Finally, we provide evidence of elevated serum growth hormone in Pkd1 mutant mice. Thus, the growth hormone/STAT5 signaling axis is a novel therapeutic target in ADPKD

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

Background The major complication of COVID-19 is hypoxaemic respiratory failure from capillary leak and alveolar oedema. Experimental and early clinical data suggest that the tyrosine-kinase inhibitor imatinib reverses pulmonary capillary leak.Methods This randomised, double-blind, placebo-controlled, clinical trial was done at 13 academic and non-academic teaching hospitals in the Netherlands. Hospitalised patients (aged >= 18 years) with COVID-19, as confirmed by an RT-PCR test for SARS-CoV-2, requiring supplemental oxygen to maintain a peripheral oxygen saturation of greater than 94% were eligible. Patients were excluded if they had severe pre-existing pulmonary disease, had pre-existing heart failure, had undergone active treatment of a haematological or non-haematological malignancy in the previous 12 months, had cytopenia, or were receiving concomitant treatment with medication known to strongly interact with imatinib. Patients were randomly assigned (1:1) to receive either oral imatinib, given as a loading dose of 800 mg on day 0 followed by 400 mg daily on days 1-9, or placebo. Randomisation was done with a computer-based clinical data management platform with variable block sizes (containing two, four, or six patients), stratified by study site. The primary outcome was time to discontinuation of mechanical ventilation and supplemental oxygen for more than 48 consecutive hours, while being alive during a 28-day period. Secondary outcomes included safety, mortality at 28 days, and the need for invasive mechanical ventilation. All efficacy and safety analyses were done in all randomised patients who had received at least one dose of study medication (modified intention-to-treat population). This study is registered with the EU Clinical Trials Register (EudraCT 2020-001236-10).Findings Between March 31, 2020, and Jan 4, 2021, 805 patients were screened, of whom 400 were eligible and randomly assigned to the imatinib group (n=204) or the placebo group (n=196). A total of 385 (96%) patients (median age 64 years [IQR 56-73]) received at least one dose of study medication and were included in the modified intention-to-treat population. Time to discontinuation of ventilation and supplemental oxygen for more than 48 h was not significantly different between the two groups (unadjusted hazard ratio [HR] 0.95 [95% CI 0.76-1.20]). At day 28, 15 (8%) of 197 patients had died in the imatinib group compared with 27 (14%) of 188 patients in the placebo group (unadjusted HR 0.51 [0.27-0.95]). After adjusting for baseline imbalances between the two groups (sex, obesity, diabetes, and cardiovascular disease) the HR for mortality was 0.52 (95% CI 0.26-1.05). The HR for mechanical ventilation in the imatinib group compared with the placebo group was 1.07 (0.63-1.80; p=0.81). The median duration of invasive mechanical ventilation was 7 days (IQR 3-13) in the imatinib group compared with 12 days (6-20) in the placebo group (p=0.0080). 91 (46%) of 197 patients in the imatinib group and 82 (44%) of 188 patients in the placebo group had at least one grade 3 or higher adverse event. The safety evaluation revealed no imatinib-associated adverse events.Interpretation The study failed to meet its primary outcome, as imatinib did not reduce the time to discontinuation of ventilation and supplemental oxygen for more than 48 consecutive hours in patients with COVID-19 requiring supplemental oxygen. The observed effects on survival (although attenuated after adjustment for baseline imbalances) and duration of mechanical ventilation suggest that imatinib might confer clinical benefit in hospitalised patients with COVID-19, but further studies are required to validate these findings. Copyright (C) 2021 Elsevier Ltd. All rights reserved.Pathogenesis and treatment of chronic pulmonary disease

/sup 1/H, /sup 19/F and /sup 11/B nuclear magnetic resonance characterization of BF/sub 3/:amine catalysts used in the cure of C fiber-epoxy prepregs

The chemical composition of commercial BF/sub 3/:amine complexes are variable and contain BF/sub 4//sup -/ and BF/sub 3/(OH)/sup -/ salts together with other unidentified highly reactive species. The BF/sub 3/:amine complexes, which are susceptible to hydrolysis, also partially convert to the BF/sub 4//sup -/ salt (i.e. BF/sub 4//sup -/NH/sub 3//sup +/C/sub 2/H/sub 5/) upon heating. This salt formation is accelerated in dimethyl sulfoxide solution and in the presence of the epoxides that are present in commercial prepregs. Commercial C fiber-epoxy prepregs are shown to contain either BF/sub 3/:NH/sub 2/C/sub 2/H/sub 5/ or BF/sub 3/:NHC/sub 5/H/sub 10/ species together with their BF/sub 4//sup -/ salts and a variety of boron-fluorine or carbon-fluorine prepreg species. Considerable variation in the relative quantities of BF/sub 3/:amine to its BF/sub 4//sup -/ salt was observed from prepreg lot to lot, which will cause variable viscosity-time-temperature prepreg cure profiles. It is concluded that the chemically stable and mobile BF/sub 4//sup -/ salt is the pre-dominant catalytic species, acting as a cationic catalyst for the prepreg cure reactions. During the early stages of cure the BF/sub 3/:amine catalyst converts to the BF/sub 4//sup -/ salt in the presence of epoxides, whereas the BF/sub 3/-prepreg species are susceptible to catalytic deactivation and immobilization

Effects of sugars and aminooxyacetic acid on the longevity of pollinated Oncidium Gower Ramsey flowers

The effects of sugars and aminooxyacetic acid (AOA) on the vase life of pollinated Oncidium Gower Ramsey flowers were investigated in this study. AOA was found to be an effective ethylene inhibitor as holding solutions containing 0.5 mM of AOA considerably prolonged the vase life of the flowers. The best treatment in delaying the senescence of pollinated Oncidium Gower Ramsey flowers were solutions of 4 sucrose + 0.5 mM AOA and 0.5 mM AOA. Both these treatments managed to delay the discolouration, furrowing and appearance of the veins up to nearly twice the length of time it took for the control flowers held in distilled water, to start senescing. The addition of glucose to the holding solution was not as effective as sucrose in delaying the senescence and prolonging the vase life of the flowers. Signs of senescence such as discolouration were measured using the Minolta chroma meter. Weight loss and pH of the holding solutions were also measured daily. AOA added in the solutions had a positive effect of lowering the pH of the holding solution thus inhibiting bacterial growth in the vial. A low pH also accounted for better water uptake by the flowers which delayed turgor loss and thus also delaying the wilting of the flowers

The theory of mind module in evolutionary psychology

The original publication can be found at www.springerlink.comEvolutionary Psychology is based on the idea that the mind is a set of special purpose thinking devices or modules whose domain-specific structure is an adaptation to ancestral environments. The modular view of the mind is an uncontroversial description of the periphery of the mind, the input-output sensorimotor and affective subsystems. The novelty of EP is the claim that higher order cognitive processes also exhibit a modular structure. Autism is a primary case study here, interpreted as a developmental failure of a module devoted to social intelligence or Theory of Mind. In this article I reappraise the arguments for innate modularity of TOM and argue that they fail. TOM ability is a consequence of domain general development scaffolded by early, innately specified, sensorimotor abilities. The alleged Modularity of TOM results from interpreting the outcome of developmental failures characteristic of autism at too high a level of cognitive abstraction.Philip Gerran

Imatinib in patients with severe COVID-19: a randomised, doubleblind, placebo-controlled, clinical trial (vol 9, pg 957, 2021)

Pathogenesis and treatment of chronic pulmonary disease